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In recent years, there has been an explosion of interest in stem cells, not just within the scientiﬁc and
medical communities but also among politicians, religious groups and ethicists. Here, we summar-
ize the different types of stem cells that have been described: their origins in embryonic and adult
tissues and their differentiation potential in vivo and in culture. We review some current clinical
applications of stem cells, highlighting the problems encountered when going from proof-of-
principle in the laboratory to widespread clinical practice. While some of the key genetic and epige-
netic factors that determine stem cell properties have been identiﬁed, there is still much to be
learned about how these factors interact. There is a growing realization of the importance of
environmental factors in regulating stem cell behaviour and this is being explored by imaging
stem cells in vivo and recreating artiﬁcial niches in vitro. New therapies, based on stem cell
transplantation or endogenous stem cells, are emerging areas, as is drug discovery based on
patient-speciﬁc pluripotent cells and cancer stem cells. What makes stem cell research so exciting
is its tremendous potential to beneﬁt human health and the opportunities for interdisciplinary
research that it presents.
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1. INTRODUCTION: WHAT ARE STEM CELLS?
The human body comprises over 200 different cell
types that are organized into tissues and organs to pro-
vide all the functions required for viability and
reproduction. Historically, biologists have been inter-
ested primarily in the events that occur prior to
birth. The second half of the twentieth century was a
golden era for developmental biology, since the key
regulatory pathways that control speciﬁcation and
morphogenesis of tissues were deﬁned at the molecular
level (Arias 2008). The origins of stem cell research lie
in a desire to understand how tissues are maintained in
adult life, rather than how different cell types arise in
the embryo. An interest in adult tissues fell, histori-
cally, within the remit of pathologists and thus
tended to be considered in the context of disease,
particularly cancer.
It was appreciated long ago that within a given
tissue there is cellular heterogeneity: in some tissues,
such as the blood, skin and intestinal epithelium, the
differentiated cells have a short lifespan and are
unable to self-renew. This led to the concept that
such tissues are maintained by stem cells, deﬁned as
cells with extensive renewal capacity and the ability
to generate daughter cells that undergo further differ-
entiation (Lajtha 1979). Such cells generate only
the differentiated lineages appropriate for the tissue
in which they reside and are thus referred to as
multipotent or unipotent (ﬁgure 1).
In the early days of stem cell research, a distinction
was generally made between three types of tissue:
those, such as epidermis, with rapid turnover of differ-
entiated cells; those, such as brain, in which there
appeared to be no self-renewal; and those, such as
liver, in which cells divided to give two daughter cells
that were functionally equivalent (Leblond 1964;
Hall & Watt 1989). While it remains true that different
adult tissues differ in terms of the proportion of prolif-
erative cells and the nature of the differentiation
compartment, in recent years it has become apparent
that some tissues that appeared to lack self-renewal
ability do indeed contain stem cells (Zhao et al.
2008) and others contain a previously unrecognized
cellular heterogeneity (Zaret & Grompe 2008). That
is not to say that all tissues are maintained by stem
cells; for example, in the pancreas, there is evidence
against the existence of a distinct stem cell compartment
(Dor et al. 2004).
One reason why it took so long for stem cells to
become a well-established research ﬁeld is that in the
early years too much time and energy were expended
in trying to deﬁne stem cells and in arguing about
whether or not a particular cell was truly a stem cell
(Watt 1999). Additional putative characteristics of
stem cells, such as rarity, capacity for asymmetric div-
ision or tendency to divide infrequently, were
incorporated into the deﬁnition, so that if a cell did
not exhibit these additional properties it tended to be
excluded from the stem cell ‘list’. Some researchers
still remain anxious about the deﬁnitions and try
to hedge their bets by describing a cell as a stem/
progenitor cell. However, this is not useful. The use
of the term progenitor, or transit amplifying, cell
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compartment but still retains the ability to undergo
cell division and further differentiation (Potten &
Loefﬂer 2008).
Looking back at some of the early collections of
reviews written as the proceedings of stem cell confer-
ences, one regularly ﬁnds articles on the topic of
cancer stem cells (McCulloch et al. 1988). However,
these cells have only recently received widespread
attention (Reya et al. 2001; Clarke et al. 2006; Dick
2008). The concept is very similar to the concept of
normal tissue stem cells, namely that cells in tumours
are heterogeneous, with only some, the cancer stem
cells, or tumour initiating cells, being capable of
tumour maintenance or regrowth following che-
motherapy. The cancer stem cell concept is
important because it suggests new approaches to
anti-cancer therapies (ﬁgure 2).
As in the case of tissue stem cells, it is important
that cancer stem cell research is not sidetracked by
arguments about deﬁnitions. It is quite likely that in
some tumours all the cells are functionally equivalent,
and there is no doubt that tumour cells, like normal
stem cells, can behave differently under different
assay conditions (Quintana et al. 2008). The oncogene
dogma (Hahn & Weinberg 2002), that tumours arise
through step-wise accumulation of oncogenic
mutations, does not adequately account for cellular
heterogeneity, and markers of stem cells in speciﬁc
cancers have already been described (Singh et al.
2004; Barabe ´ et al. 2007; O’Brien et al. 2007). While
the (rediscovered) cancer stem cell ﬁeld is currently
in its infancy, it is already evident that a cancer stem
cell is not necessarily a normal stem cell that has
acquired oncogenic mutations. Indeed, there is exper-
imental evidence that cancer initiating cells can be
genetically altered progenitor cells (Clarke et al. 2006).
In addition to adult tissue stem cells, stem cells can
be isolated from pre-implantation mouse and human
embryos and maintained in culture as undifferentiated
cells (ﬁgure 1). Such embryonic stem (ES) cells have
the ability to generate all the differentiated cells of
the adult and are thus described as being pluripotent
(ﬁgure 1). Mouse ES cells are derived from the inner
cell mass of the blastocyst, and following their discov-
ery in 1981 (Evans & Kaufman 1981; Martin 1981)
have been used for gene targeting, revolutionizing the
ﬁeld of mouse genetics. In 1998, it was ﬁrst reported
that stem cells could be derived from human blasto-
cysts (Thomson et al. 1998), opening up great
opportunities for stem cell-based therapies, but also
provoking controversy because the cells are derived
from ‘spare’ in vitro fertilization embryos that have
the potential to produce a human being. It is interest-
ing to note that, just as research on adult tissue stem
cells is intimately linked to research on disease states,
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Figure 1. Origin of stem cells. Cells are described as pluripotent if they can form all the cell types of the adult organism. If, in
addition, they can form the extraembryonic tissues of the embryo, they are described as totipotent. Multipotent stem cells have
the ability to form all the differentiated cell types of a given tissue. In some cases, a tissue contains only one differentiated lin-
eage and the stem cells that maintain the lineage are described as unipotent. Postnatal spermatogonial stem cells, which are
unipotent in vivo but pluripotent in culture, are not shown (Jaenisch & Young 2008). CNS, central nervous system; ICM,
inner cell mass.
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years before the development of ES cells, the in vitro
differentiation of cells derived from teratocarcinomas,
known as embryonal carcinoma cells, provided an
important model for studying lineage selection
(Andrews et al. 2005).
Blastocysts are not the only source of pluripotent
ES cells (ﬁgure 1). Pluripotent epiblast stem cells,
known as epiSC, can be derived from the post-
implantation epiblast of mouse embryos (Brons et al.
2007; Tesar et al. 2007). Recent gene expression
proﬁling studies suggest that human ES cells are
more similar to epiSC than to mouse ES cells (Tesar
et al. 2007). Pluripotent stem cells can also be derived
from primordial germ cells (EG cells), progenitors of
adult gametes, which diverge from the somatic lineage
at late embryonic to early foetal development (Kerr
et al. 2006).
Although in the past the tendency has been to
describe ES cells as pluripotent and adult stem cells
as having a more restricted range of differentiation
options, adult cells can, in some circumstances, pro-
duce progeny that differentiate across the three
primary germ layers (ectoderm, mesoderm and endo-
derm). Adult cells can be reprogrammed to a
pluripotent state by transfer of the adult nucleus into
the cytoplasm of an oocyte (Gurdon et al. 1958;
Gurdon & Melton 2008) or by fusion with a
pluripotent cell (Miller & Ruddle 1976). The most
famous example of cloning by transfer of a somatic
nucleus into an oocyte is the creation of Dolly
the sheep (Wilmut et al. 1997). While the process
remains inefﬁcient, it has found some unexpected
applications, such as cloning endangered species and
domestic pets.
A ﬂurry of reports almost 10 years ago suggested
that adult cells from many tissues could differentiate
into other cell types if placed in a new tissue environ-
ment. Such studies are now largely discredited,
although there are still some bona ﬁde examples
of transdifferentiation of adult cells, such as occurs
when blood cells fuse with hepatocytes during repair
of damaged liver (Anderson et al. 2001; Jaenisch &
Young 2008). In addition, it has been known for
many years that adult urodele amphibians can regener-
ate limbs or the eye lens following injury; this involves
dedifferentiation and subsequent transdifferentiation
steps (Brockes & Kumar 2005).
The early studies involving somatic nuclear transfer
indicated that adult cells can be reprogrammed to
pluripotency. However, the mechanistic and practical
applications of inducing pluripotency in adult cells
have only become apparent in the last 2 or 3 years,
with the emergence of a new research area: induced
pluripotent stem cells (iPS cells). The original report
demonstrated that retrovirus-mediated transduction
of mouse ﬁbroblasts with four transcription factors
(Oct-3/4, Sox2, KLF4 and c-Myc; ﬁgure 1)t h a ta r e
highly expressed in ES cells could induce the ﬁbroblasts
to become pluripotent (Takahashi & Yamanaka 2006).
Since then, rapid progress has been made: iPS cells
can be generated from adult human cells (Takahashi
et al. 2007; Yu et al.2 0 0 7 ; Park et al.2 0 0 8 a); cells
from a range of tissues can be reprogrammed
(Aasen et al.2 0 0 8 ; Aoi et al.2 0 0 8 ); and iPS cells can
be generated from patients with speciﬁc diseases
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Figure 2. The cancer stem cell hypothesis. The upper tumour is shown as comprising a uniform population of cells, while the
lower tumour contains both cancer stem cells and more differentiated cells. Successful or unsuccessful chemotherapy is
interpreted according to the behaviour of cells within the tumour.
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transcription factors required to generate iPS cells has
been reduced (Kim et al.2 0 0 8 ); the efﬁciency of iPS
cell generation increased (Wernig et al.2 0 0 7 ); and tech-
niques devised that obviate the need for retroviral
vectors (Okita et al.2 0 0 8 ; Stadtfeld et al.2 0 0 8 ).
These latter developments are very important for
future clinical applications, since the early mice gener-
ated from iPS cells developed tumours at high
frequency (Takahashi & Yamanaka 2006; Yamanaka
2007). Without a doubt, this is currently the most
exciting and rapidly moving area of stem cell research.
2. CURRENT CLINICAL APPLICATIONS
OF STEM CELLS
In all the publicity that surrounds embryonic and iPS
cells, people tend to forget that stem cell-based thera-
pies are already in clinical use and have been for
decades. It is instructive to think about these treat-
ments, because they provide important caveats about
the journey from proof-of-principle in the laboratory
to real patient beneﬁt in the clinic. These caveats
include efﬁcacy, patient safety, government legislation
and the costs and potential proﬁts involved in patient
treatment.
Haemopoietic stem cell transplantation is the oldest
stem cell therapy and is the treatment that is most
widely available (Perry & Linch 1996; Austin et al.
2008). The stem cells come from bone marrow, per-
ipheral blood or cord blood. For some applications,
the patient’s own cells are engrafted. However, allo-
geneic stem cell transplantation is now a common
procedure for the treatment of bone marrow failure
and haematological malignancies, such as leukaemia.
Donor stem cells are used to reconstitute immune
function in such patients following radiation and/or
chemotherapy. In the UK, the regulatory framework
put in place for bone marrow transplantation has
now an extended remit, covering the use of other
tissues and organs (Austin et al. 2008).
Advances in immunology research greatly increased
the utility of bone marrow transplantation, allowing
allograft donors to be screened for the best match in
order to prevent rejection and graft-versus-host disease
(Perry & Linch 1996). It is worth remembering that
organ transplantation programmes have also depended
on an understanding of immune rejection, and drugs
are available to provide effective long-term immuno-
suppression for recipients of donor organs. Thus,
while it is obviously desirable for new stem cell treat-
ments to involve the patient’s own cells, it is certainly
not essential.
Two major advantages of haemopoietic stem cell
therapy are that there is no need to expand the cells
in culture or to reconstitute a multicellular tissue
architecture prior to transplantation. These hurdles
have been overcome to generate cultured epidermis
to provide autologous grafts for patients with
full-thickness wounds, such as third-degree burns.
Proof-of-principle was established in the mid-1970s,
with clinical and commercial applications following
rapidly (Green 2008). Using a similar approach,
limbal stem cells have been used successfully to restore
vision in patients suffering from chemical destruction
of the cornea (De Luca et al. 2006).
Ex vivo expansion of human epidermal and corneal
stem cells frequently involves culture on a feeder layer
of mouse ﬁbroblastic cells in medium containing
bovine serum. While it would obviously be preferable
to avoid animal products, there has been no evidence
over the past 30 years that exposure to them has had
adverse effects on patients receiving the grafts. The
ongoing challenges posed by epithelial stem cell treat-
ments include improved functionality of the graft (e.g.
through generation of epidermal hair follicles) and
improved surfaces on which to culture the cells and
apply them to the patients. The need to optimize
stem cell delivery is leading to close interactions
between the stem cell community and bioengineers.
In a recent example, a patient’s trachea was repaired
by transplanting a new tissue constructed in culture
from donor decellularized trachea seeded with the
patient’s own bone marrow cells that had been differ-
entiated into cartilage cells (Macchiarini et al. 2008).
Whereas haemopoietic stem cell therapies are
widely available, treatments involving cultured epider-
mis and cornea are not. In countries where cultured
epithelial grafts are available, the number of potential
patients is relatively small and the treatment costly.
Commercial organizations that sell cultured epidermis
for grafting have found that it is not particularly proﬁt-
able, while in countries with publicly funded
healthcare the need to set up a dedicated laboratory
to generate the grafts tends to make the ﬁnancial
cost–beneﬁt ratio too high (Green 2008).
Clinical studies over the last 10 years suggest that
stem cell transplantation also has potential as a therapy
for neurodegenerative diseases. Clinical trials have
involved grafting brain tissue from aborted foetuses
into patients with Parkinson’s disease and Hunting-
ton’s disease (Dunnett et al. 2001; Wright & Barker
2007). While some successes have been noted, the
outcomes have not been uniform and further clinical
trials will involve more reﬁned patient selection, in
an attempt to predict who will beneﬁt and who will
not. Obviously, aside from the opposition in many
quarters to using foetal material, there are practical
challenges associated with availability and uniformity
of the grafted cells and so therapies with pure popu-
lations of stem cells are an important, and achievable
(Conti et al. 2005; Lowell et al. 2006), goal.
No consideration of currently available stem cell
therapies is complete without reference to gene
therapy. Here, there have been some major achieve-
ments, including the successful treatment of children
with X-linked severe combined immunodeﬁciency.
However, the entire gene therapy ﬁeld stalled when
several of the children developed leukaemia as a
result of integration of the therapeutic retroviral
vector close to the LMO2 oncogene locus (Gaspar &
Thrasher 2005; Pike-Overzet et al. 2007). Clinical
trials have since restarted, and in an interesting
example of combined gene/stem cell therapy, a patient
with an epidermal blistering disorder received an auto-
logous graft of cultured epidermis in which the
defective gene had been corrected ex vivo (Mavilio
et al. 2006).
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ving stem cells that are already in the clinic. They
show how the ﬁeld of stem cell transplantation is
interlinked with the ﬁelds of gene therapy and bio-
engineering, and how it has beneﬁted from progress
in other ﬁelds, such as immunology. Stem cells
undoubtedly offer tremendous potential to treat
many human diseases and to repair tissue damage
resulting from injury or ageing. The danger, of
course, lies in the potentially lethal cocktail of despe-
rate patients, enthusiastic scientists, ambitious
clinicians and commercial pressures (Lau et al.
2008). Internationally agreed, and enforced, regu-
lations are essential in order to protect patients from
the dangers of stem cell tourism, whereby treatments
that have not been approved in one country are
freely available in another (Hyun et al. 2008).
3. WHAT ARE THE BIG QUESTIONS
IN THE FIELD?
Three questions in stem cell research are being hotly
pursued at present. What are the core genetic and epi-
genetic regulators of stem cells? What are the extrinsic,
environmental factors that inﬂuence stem cell renewal
and differentiation? And how can the answers to the
ﬁrst two questions be harnessed for clinical beneﬁt?
4. CORE GENETIC AND EPIGENETIC
REGULATORS
Considerable progress has already been made in
deﬁning the transcriptional circuitry and epigenetic
modiﬁcations associated with pluripotency (Jaenisch &
Young 2008). This research area is moving very rapidly
as a result of tremendous advances in DNA sequen-
cing technology, bioinformatics and computational
biology. Chromatin immunoprecipitation combined
with microarray hybridization or DNA sequencing
(Mathur et al. 2008) is being used to identify transcrip-
tion factor-binding sites, and bioinformatics
techniques have been developed to allow integration
of data obtained by the different approaches. It is
clear that pluripotency is also subject to complex
epigenetic regulation, and high throughput genome-
scale DNA methylation proﬁling has been developed
for epigenetic proﬁling of ES cells and other cell
types (Meissner et al. 2008).
Oct4, Nanog and Sox2 are core transcription
factors that maintain pluripotency of ES cells. These
factors bind to their own promoters, forming an auto-
regulatory loop. They occupy overlapping sets of target
genes, one set being actively expressed and the other,
comprising genes that positively regulate lineage selec-
tion, being actively silenced (Jaenisch & Young 2008;
Mathur et al. 2008; Silva & Smith 2008). Nanog
stabilizes pluripotency by limiting the frequency with
which cells commit to differentiation (Chambers
et al. 2007; Torres & Watt 2008). The core pluripo-
tency transcription factors also regulate, again
positively and negatively, the microRNAs that are
involved in controlling ES cell self-renewal and
differentiation (Marson et al. 2008).
As the basic mechanisms that maintain the pluripo-
tent state of ES cells are delineated, there is
considerable interest in understanding how pluripo-
tency is re-established in adult stem cells. It appears
that some cell types are more readily reprogrammed
to iPS cells than others (Aasen et al. 2008; Aoi et al.
2008), and it is interesting to speculate that this
reﬂects differences in endogenous expression of the
genes required for reprogramming or in responsiveness
to overexpression of those genes (Hochedlinger et al.
2005; Markoulaki et al. 2009). Another emerging
area of investigation is the relationship between the
epigenome of pluripotent stem cells and cancer cells
(Meissner et al. 2008).
Initial attempts at deﬁning ‘stemness’ by comparing
the transcriptional proﬁles of ES cells, neural and
haemopoietic stem cells (Ivanova et al. 2002;
Ramalho-Santos et al. 2002) have paved the way for
more reﬁned comparisons. For example, by comparing
the gene expression proﬁles of adult neural stem cells,
ES-derived and iPS-derived neural stem cells and brain
tumour stem cells, it should be possible both to validate
the use of ES-derived stem cells for brain repair and to
establish the cell of origin of brain tumour initiating
cells. Furthermore, it is anticipated that new therapeutic
targetswillbe identiﬁedfrommolecular proﬁlingstudies
of different stem cell populations.
As gene expression proﬁling becomes more sophis-
ticated, the question of ‘what is a stem cell?’ can be
addressed in new ways. Several studies have used
single cell expression microarrays to identify new
stem cell markers (Jensen & Watt 2006). Stem cells
are well known to exhibit different proliferative and
differentiation properties in culture, during tissue
injury and in normal tissue homeostasis, raising the
question of which elements of the stem cell phenotype
are hard-wired versus a response to environmental
conditions.
One of the growing trends in stem cell research is
the contribution of mathematical modelling. This is
illustrated in the concept of transcriptional noise: the
hypothesis that intercellular variability is a manifes-
tation of ‘noise’ in gene expression levels, rather than
stable phenotypic variation (Chang et al. 2008).
Studies with clonal populations of haemopoietic pro-
genitor cells have shown that slow ﬂuctuations in
protein levels can produce cellular heterogeneity that
is sufﬁcient to affect whether a given cell will differen-
tiate along the myeloid or erythroid lineage (Chang
et al. 2008). Mathematical approaches are also used
increasingly to model observed differences in cell
behaviour in vivo. In studies of adult mouse interfolli-
cular epidermis, it is observed that cells can divide to
produce two undifferentiated cells, two differentiated
cells or one of each (ﬁgure 3); it turns out that this
can be explained in terms of the stochastic behaviour
of a single population of cells rather than by invoking
the existence of discrete types of stem and progenitor
cell (Clayton et al. 2007).
5. EXTRINSIC REGULATORS
There is strong evidence that the behaviour of stem
cells is strongly affected by their local environment or
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ment that are known to inﬂuence self-renewal and
stem cell fate are adhesion to extracellular matrix pro-
teins, direct contact with neighbouring cells, exposure
to secreted factors and physical factors, such as oxygen
tension and sheer stress (Watt & Hogan 2000;
Morrison & Spradling 2008). It is important to identify
the environmental signals that control stem cell expan-
sionanddifferentiationinorder toharnessthosesignals
to optimize delivery of stem cell therapies.
Considerable progress has been made in directing
ES cells to differentiate along speciﬁc lineages in vitro
(Conti et al. 2005; Lowell et al. 2006; Izumi et al.
2007) and there are many in vitro and murine
models of lineage selection by adult tissue stem cells
(e.g. Watt & Collins 2008). It is clear that in many
contexts the Erk and Akt pathways are key regulators
of cell proliferation and survival, while pathways that
were originally deﬁned through their effects in
embryonic development, such as Wnt, Notch and
Shh, are reused in adult tissues to inﬂuence stem cell
renewal and lineage selection. Furthermore, these
core pathways are frequently deregulated in cancer
(Reya et al. 2001; Watt & Collins 2008). In investi-
gating how differentiation is controlled, it is not only
the signalling pathways themselves that need to be
considered, but also the timing, level and duration of
a particular signal, as these variables profoundly inﬂu-
ence cellular responses (Silva-Vargas et al. 2005). A
further issue is the extent to which directed ES cell
differentiation in vitro recapitulates the events that
occur during normal embryogenesis and whether this
affects the functionality of the differentiated cells
(Izumi et al. 2007).
For a more complete deﬁnition of the stem cell
niche, researchers are taking two opposite and comp-
lementary approaches: recreating the niche in vitro at
the single cell level and observing stem cells in vivo.
In vivo tracking of cells is possible because of
advances in high-resolution confocal microscopy and
two-photon imaging, which have greatly increased
the sensitivity of detecting cells and the depth of the
tissue at which they can be observed. Studies of green
ﬂuorescent protein-labelled haemopoietic stem cells
have shown that their relationship with the bone
marrow niche, comprising blood vessels, osteoblasts
and the inner bone surface, differs in normal, irradiated
and c-Kit-receptor-deﬁcient mice (Lo Celso et al.2 0 0 9 ;
Xie et al.2 0 0 9 ). In a different approach, in vivo biolu-
minescence imaging of luciferase-tagged muscle stem
cells has been used to reveal their role in muscle
repair in a way that is impossible when relying on
retrospective analysis of ﬁxed tissue (Sacco et al. 2008).
The advantage of recreating the stem cell niche in
vitro is that it is possible to precisely control individual
aspects of the niche and measure responses at the
single cell level. Artiﬁcial niches are constructed by
plating cells on micropatterned surfaces or capturing
them in three-dimensional hydrogel matrices. In this
way, parameters such as cell spreading and substrate
mechanics can be precisely controlled (Watt et al.
1988; The ´ry et al. 2005; Chen 2008). Cells can be
exposed to speciﬁc combinations of soluble factors or
to tethered recombinant adhesive proteins. Cell behav-
iour can be monitored in real time by time-lapse
microscopy, and activation of speciﬁc signalling path-
ways can be viewed using ﬂuorescence resonance
energy transfer probes and ﬂuorescent reporters of
transcriptional activity. It is also possible to recover
cells from the in vitro environment, transplant them
in vivo and monitor their subsequent behaviour. One
of the exciting aspects of the reductionist approach to
studying the niche is that it is highly interdisciplinary,
bringing together stem cell researchers and bioengi-
neers, and also offering opportunities for interactions
with chemists, physicists and materials scientists.
6. FUTURE CLINICAL APPLICATIONS OF
STEM CELL RESEARCH
Almost every day there are reports in the media of new
stem cell therapies. There is no doubt that stem cells
have the potential to treat many human afﬂictions,
including ageing, cancer, diabetes, blindness and
physical forces
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Figure 3. The stem cell niche. Stem cells (S) are shown dividing symmetrically to produce two stem cells (1) or two differen-
tiated cells (D) (2), or undergoing asymmetric division to produce one stem cell and one differentiated cell (3). Under some
circumstances, a differentiated cell can re-enter the niche and become a stem cell (4). Different components of the stem cell
niche are illustrated: extracellular matrix (ECM), cells in close proximity to stem cells (niche cells), secreted factors (such as
growth factors) and physical factors (such as oxygen tension, stiffness and stretch).
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realistic about the time and steps required to take
new therapies into the clinic: it is exciting to be able
to induce ES cells to differentiate into cardiomyocytes
in a culture dish, but that is only one very small step
towards effecting cardiac repair. The overriding con-
cerns for any new treatment are the same: efﬁcacy,
safety and affordability.
In January 2009, the US Food and Drug Adminis-
tration approved the ﬁrst clinical trial involving human
ES cells, just over 10 years after they were ﬁrst isolated.
In this trial, the safety of ES cell-derived oligodendro-
cytes in repair of spinal cord injury will be evaluated
(http://www.geron.com). There are a large number of
human ES cell lines now in existence and banking of
clinical grade cells is underway, offering the opportu-
nity for optimal immunological matching of donors
and recipients. Nevertheless, one of the attractions of
transplanting iPS cells is that the patient’s own cells
can be used, obviating the need for immunosuppres-
sion. Discovering how the pluripotent state can be
efﬁciently and stably induced and maintained by treat-
ing cells with pharmacologically active compounds
rather than by genetic manipulation is an important
goal (Silva et al. 2008).
An alternative strategy to stem cell transplantation
is to stimulate a patient’s endogenous stem cells to
divide or differentiate, as happens naturally during
skin wound healing. It has recently been shown that
pancreatic exocrine cells in adult mice can be repro-
grammed to become functional, insulin-producing
beta cells by expression of transcription factors that
regulate pancreatic development (Zhou et al. 2008).
The idea of repairing tissue through a process of cellu-
lar reprogramming in situ is an attractive paradigm to
be explored further.
A range of biomaterials are already in clinical use
for tissue repair, in particular to repair defects in car-
tilage and bone (Kamitakahara et al. 2008). These
can be considered as practical applications of our
knowledge of the stem cell microenvironment.
Advances in tissue engineering and materials science
offer new opportunities to manipulate the stem niche
and either facilitate expansion/differentiation of
endogenous stem cells or deliver exogenous cells.
Resorbable scaffolds can be exploited for controlled
delivery and release of small molecules, growth factors
and peptides. Conversely, scaffolds can be designed
that are able to capture unwanted tissue debris that
might impede repair. Hydrogels that can undergo con-
trolled sol–gel transitions could be used to release
stem cells once they have integrated within the target
tissue.
Although most of the new clinical applications of
stem cells have a long lead time, applications of stem
cells in drug discovery are available immediately.
Adult tissue stem cells, ES cells and iPS cells can all
be used to screen for compounds that stimulate self-
renewal or promote speciﬁc differentiation pro-
grammes. Finding drugs that selectively target cancer
stem cells offers the potential to develop cancer treat-
ments that are not only more effective, but also
cause less collateral damage to the patient’s normal
tissues than drugs currently in use. In addition,
patient-speciﬁc iPS cells provide a new tool to identify
underlying disease mechanisms. Thus stem cell-based
assays are already enhancing drug discovery efforts.
7. CONCLUSION
Amid all the hype surrounding stem cells, there are
strong grounds for believing that over the next 50
years our understanding of stem cells will revolutionize
medicine. One of the most exciting aspects of working
in the stem cell ﬁeld is that it is truly multidisciplinary
and translational. It brings together biologists, clini-
cians and researchers across the physical sciences and
mathematics, and it fosters partnerships between aca-
demics and the biotech and pharmaceutical industries.
In contrast to the golden era of developmental biology,
one of stem cell research’s deﬁning characteristics is
the motivation to beneﬁt human health.
We thank all members of our lab, past and present, for their
energy, fearlessness and intellectual curiosity in the pursuit
of stem cells. We are grateful to Cancer Research UK, the
Wellcome Trust, MRC and European Union for ﬁnancial
support and to members of the Cambridge Stem Cell
Initiative for sharing their ideas.
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